Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by JGP Wealth Management LLC

JGP Wealth Management LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 2,051 shares of the medical equipment provider’s stock after acquiring an additional 84 shares during the quarter. JGP Wealth Management LLC’s holdings in Intuitive Surgical were worth $1,008,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Creekmur Asset Management LLC grew its stake in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $26,000. Able Wealth Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $28,000. Delos Wealth Advisors LLC grew its position in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares during the period. Finally, LRI Investments LLC purchased a new position in Intuitive Surgical in the first quarter valued at about $30,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $0.36 during trading hours on Friday, reaching $484.20. The company’s stock had a trading volume of 357,323 shares, compared to its average volume of 1,464,928. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.48. The company’s 50 day simple moving average is $479.63 and its 200 day simple moving average is $434.04. The stock has a market cap of $172.06 billion, a P/E ratio of 83.36, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the firm posted $1.18 EPS. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $482.21, for a total transaction of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,655,048.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last three months. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on ISRG shares. Truist Financial boosted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Barclays lifted their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Piper Sandler raised their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. JPMorgan Chase & Co. upped their target price on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $458.35.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.